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mary profile we used the data of frequency by age and gender for this specialised 
profile obtaining this from the minimum joint data base of the hospital discharge. 
The profile of the pharmaceutical expenditure by age and gender was obtained 
from the pharmacy invoice, once the public contribution was deducted. The esti-
mated population in 10 years was obtained from the National Statistic Institute. 
(INE). Results: aging results in a cumulative annual rate for the period 2011-2021 
for public health expenditure growth of 5.34%. The aging effect implies a cumula-
tive annual rate in the period 2011-2021 of 6.43% and a decrease of -0.69% due to 
the range effect (decrease in population). Of all the segments, the largest increase 
is in the pharmaceutical costs with an accumulated increase of 8.81%, of which 
5,65% is in primary attention and 4,78% in specialised attention. ConClusions: 
According to our results, population growth or aging are determining aspects in 
public health expenditure increase. Using data directly from each region will explain 
the differences. In the case of Extremadura, the age factor is very important when 
increasing the pressure of the public health cost, having a special influence in the 
field of pharmaceutical expenditure and primary attention.
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KazaKHstan VersUs UzbeKIstan: a reVIew of tHe DrUg ProVIsIon 
systems
Rainova K., Izmirlieva M., Ando G.
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objeCtives: As is the case with many of the Commonwealth of Independent 
Countries (CIS), since the collapse of the Soviet Union, both Kazakhstan and 
Uzbekistan have been re-building health care provision, and improving access 
to medications for their population. This study compares the two separate paths 
the countries have taken, and aims to establish the outcomes achieved by the 
two systems as well as the direction of future reforms. Methods: Secondary 
research focused on analysing the systems in place in the two countries, focus-
ing on drug provision. The study assessed the mechanisms in place, drawing 
comparisons between the two systems, with a particular focus on the outcomes 
achieved. Results: Uzbekistan provides medications free of cost for certain catego-
ries of patients, while in Kazakhstan, the government has approved a list of drugs 
that are provided for free as part of the guaranteed volume of free medical care. In 
both the cases these fall under an outpatient setting. Although the procurement of 
drugs is carried out mostly via tenders, Kazakhstan’s system involves establishing 
price ceilings. In Uzbekistan, retail and wholesale margins are controlled. Between 
2002-2012, public health expenditure as a percentage of total health expenditure 
rose from 54% to 58% in Kazakhstan and from 45% to 53% in Uzbekistan. Life expec-
tancy however, increased from 65.9 to 69.6 years in Kazakhstan and from 67.1 to 68.1 
years in Uzbekistan. ConClusions: With growing government health expendi-
ture, reflecting the expansion of the health care systems, the countries are likely 
to increasingly look into containing costs. Given that some pricing mechanism 
is already in place in Kazakhstan, it may consider implementing tighter pricing 
regulations, moving closer to those seen in Europe. In Uzbekistan, the government 
may potentially consider expanding the beneficiary categories while ensuring com-
petiveness within the tendering process.
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objeCtives: The Cervantes scale is a specific health-related-quality-of-life (HRQoL) 
questionnaire developed in Spanish women through and beyond menopause. The 
original 31-item scale was reduced to a less time consuming 16-item sort form: 
The Cervantes-SF. The aim of this work was to assess the psychometric properties 
of the Cervantes-SF in a routine clinical sample of perimenopause and postmeno-
pause women. Methods: Peri and postmenopause adult women were recruited in 
twelve outpatient clinics of Gynecology. All of the patients completed both scales, 
the 31-items form and the abridged version, however, order of administration was 
balanced equally to avoid administration bias. A sub-sample of 31 women answered 
the sort form within 1-2 weeks later (rete-test). Correlation between forms and test-
retest reliability were used to test measurement stability. Item analysis, internal 
consistency reliability, item-total and item-domain correlations and item correla-
tion with the generic Spanish version of the EQ-5D-3L questionnaire were also 
studied. Results: A sample of 215 women [mean age 55 years old (SD= 5.3)] was 
enrolled. Internal consistency was good (Cronbach’s a= 0.829) but slightly lower than 
that of the original scale (a= 0.895). Dimension reliabilities ranged between a= 0.636 
(Health) and a= 0.923 (Vasomotor). Correlations between extended and reduced 
subscales was high and significant in all cases (p< 0.001), ranging from r= 0.790 for 
Health to r= 0.872 for Vasomotor. Correlation between total scores was also high 
(r= 0.885) and no differences were found between mean scores (Effect size= 0.353). 
Short-form total score correlation with EQ-5D utility score was negative and signifi-
cant (r= -0.487) and also with EQ-5D Health VAS (r= -0.432). Test-retest correlation 
was high (r= 0.886). Completion of Cervantes-SF required half of the time than the 
original scale. ConClusions: The abridged 16-item Cervantes scale (Cervantes-SF) 
maintained the original psychometric properties. This version extends 51% of the 
original length, being faster to apply and making it specially suitable for routine 
medical practice.
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perspective) for the standard fertility treatment strategy is about 50M USD com-
pared to the fast track fertility treatment strategy at about 41M USD for a net budget 
impact of 9M USD. The average cost per patient per year (patient perspective) for 
the standard fertility treatment strategy is approximately 4,800 USD compared to 
the fast track fertility treatment strategy at an estimated 4,200 USD for a net budget 
impact of approximately 600 USD. Results vary upon user inputs. ConClusions: 
An Excel-based model was developed to assist managed care organizations and 
employers with the development of an optimal fertility benefit design. The model 
serves as an educational tool to evaluate various fertility benefit designs in terms 
of patient and financial outcomes.
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objeCtives: Older people are vulnerable to medicine-related adverse effects. In 
response to these concerns, prescribing indicators have been developed address-
ing: Potentially Inappropriate Medicines (PIMs), medicines with unfavourable risk-
benefit ratios and Potential Prescribing Omissions (PPOs), omission of indicated 
medicines with a clear benefit. Little is known about the impact of PIMs and PPOs 
on health care utilization. This study aims to determine the association between 
PIMs and PPOs and health care utilization. Methods: This is a retrospective cohort 
study of 2,051 community-dwelling participants in The Irish Longitudinal Study on 
Ageing (TILDA) aged ≥ 65 years with linked medication dispensing history from a 
national pharmacy claims database. PIM and PPO exposure in the 12 months prior 
to participants’ TILDA interviews was determined using validated prescribing indi-
cators: Screening Tool for Older Persons’ Prescriptions (STOPP), the Screening Tool 
to Alert doctors to Right Treatment (START), Beers’ criteria and Assessing Care of 
Vulnerable Elders (ACOVE) indicators. Outcome measures used were self-reported 
number of hospital visits (emergency department or inpatient admissions) and 
general practitioner (GP) visits in the previous year. Poisson regression models were 
used to determine the associations between PIMs and PPOs and these outcomes, 
adjusting for age, sex, education, number of medications, chronic conditions, and 
health insurance status. Results: Overall PIM prevalence was 19.8-52.7% and PPO 
prevalence was 43.6-44.8% depending on the screening tool applied. Independent 
of screening tool used, PIMs and PPOs were significantly associated with hospi-
tal visits. For example, the adjusted Incident Rate Ratio (IRR) for each additional 
STOPP PIM was 1.24 (95%CI= 1.15-1.35). With the exception of START PPOs, PIM and 
PPO exposure were also significantly associated with GP visits (adjusted IRR= 1.10 
(95%CI= 1.06-1.15) for each additional Beers’ PIM for example). ConClusions: PIM/
PPO exposure is independently associated with increased health care utilization, 
supporting application of PIM/PPO indicators as robust measures of health care 
quality and patient safety in relation to prescribed medications.
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objeCtives: Assisted reproductive therapy (ART) has increased dramatically in 
the US over the past several decades, nearly doubling from 1999 to 2008. Prior 
research has evaluated multiple outcomes from ART including newborn survival 
and birth weight as well as cost analyses measuring cost per live birth; despite 
robust information on ART as a whole there is no Colorado-specific data on neo-
natal intensive care unit (NICU) outcomes following ART and its economic impli-
cations. Methods: Using data from the Colorado Department of Public Health 
and Environment (CDPHE) - Colorado Birth Certificate Database from 2007-2012, 
we use multivariable logistic regression to determine if ART births are associ-
ated with a higher risk of NICU admission compared to non-ART (no fertility 
treatment) births. We compare the risk of NICU admission among the full birth 
cohort and a singleton-only cohort controlling for plural births and birth order. 
We use Colorado state Health Care Policy and Financing (HCPF) fiscal year 2007-08, 
Colorado Centre for Reproductive Medicine costs and Colorado State Medicaid 2012 
fee schedule data to estimate average NICU admission rates, total ART procedural 
costs and average costs of delivery, respectively. Results: 190,795 live births in 
2007-2012 were included into the birth cohort for analysis (12,666 ART births; 
178,129 non-ART births). ART births resulted in a 52% increased risk of being 
admitted to the NICU compared to non-ART births (OR 1.52 [95% CI 1.38,1. 69]); 
singleton-only ART births had a 39% greater risk of being admitted to the NICU 
compared with singleton non-ART births (OR 1.39 [95% CI 1.18,1. 65]). Average 
NICU admission costs were estimated at $ 6,165.78 per ART birth and $ 331.85 per 
non-ART birth. ConClusions: ART births in Colorado have a higher risk of NICU 
admission compared to non-ART births. The economic impact of NICU admissions 
is 18.6 times greater among ART births compared to non-ART births.
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objeCtives: To estimate the effect of demographic component in the evolution 
of public health expenditure of Extremadura in the period 2011-21 Methods: we 
estimated health expenditure profiles by age and gender in 2011. Then, we used 
population projections to calculate future health spending. To obtain those profiles 
we used data obtained from the information systems of Extremadura. For the pri-
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objeCtives: To estimate the calcium levels in peri menopausal and postmeno-
pausal women and to evaluate the need for calcium supplementation among 
them. Methods: A prospective study was conducted at gynecology department of 
a tertiary care hospital for the period of six months to estimate the serum calcium 
levels among them. Study populations were divided in to perimenopausal and post 
menopausal group. All the eligible patients were enrolled after obtaining informed 
consent. Study subjects from both the group were estimated for serum calcium 
levels to identify if they need calcium supplements. Unpaired T test was performed 
to find out any significant difference between both groups and pearson’s corre-
lation cofficient (r) was applied to assess the relation between age and calcium 
levels. Results: During the study period, 53 of 100 patients enrolled were postmen-
opausal with the mean age of 60.8±10.47 years and 47 of 100 patients enrolled were 
perimenopausal with mean age of 44.6±3.54 years. The mean calcium level of 47 
perimenopausal women was found to be 9.32±0.55 (reference level: 8.0-11.0 mg/dl) 
and 8.56±0.54 for 53 postmenopausal women. In post menopausal women there 
was highly significant drop observed in serum calcium levels with increasing age, 
compared to peri menopausal women. (CI: 95%, p< 0.0001, r: -0.81). ConClusions: 
The serum concentrations of calcium in majority of our study population were 
within the normal range. There was a good source of dietary intake of calcium in 
most of the patients. The levels of calcium were lower in postmenopausal women 
compared to perimenopausal women. Since there is an negative effect of calcium 
on the bone mineral density in postmenopausal women, it can be recommended 
that calcium supplementation can be given as prophylaxis to prevent the long 
term bone loss and to decrease the risk of fracture and osteoporosis.
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objeCtives: Describe patient characteristics and medication treatment 
patterns among newly diagnosed cases of BPH-LUTS, ED, and co-occurring ED 
and BPH-LUTS. Methods: Retrospective cohort study using UK CPRD data on 
incident BPH-LUTS and incident ED patients indexed between June 2010 and 
May 2011. Patient records were analysed from 12 months pre-index and up to 
24 months post-index. Results: The cohort included 8912 men with BPH-LUTS-only, 
2589 with an ED diagnosis followed by BPH-LUTS, 8093 with ED-only and 1641 
with a BPH-LUTS diagnosis followed by ED, all aged ≥ 40 years. The majority of 
BPH-LUTS patients (~90%) were diagnosed and managed within GP practices. 
Men were diagnosed with BPH-LUTS alone at an older average age (68±11.9 years, 
IQR= 59–77) compared to men in the ED/BPH-LUTS group (67±9.5 years, IQR= 61–74, 
p= 0.002). Men were diagnosed with ED at an older average age (65±9.2 years, 
IQR= 59–72) in the BPH-LUTS/ED group compared with ED-only patients (57±9.1 
years, IQR= 50–64, p< 0.001). Time between diagnoses was longer for ED/BPH-LUTS 
patients (6.8±4.76 years) versus BPH-LUTS/ED patients (5.8±5.10 years). BPH-LUTS 
and ED treatment patterns were similar for patients with and without co-occurring 
conditions. Most patients were initially prescribed alpha-blockers (62.9% BPH-
only, 65.5% ED/BPH-LUTS) or anticholinergics (14.9% BPH-only, 14.0% ED/BPH-
LUTS). For ED, most patients were initially prescribed sildenafil (51.6% ED-only, 
49.6% BPH-LUTS/ED) or tadalafil (24.3% ED-only, 26.0% BPH-LUTS/ED). At six 
months post-diagnosis, ~47% incident BPH-LUTS patients and ~78% ED patients 
were not on any BPH-LUTS or ED treatment, respectively. ConClusions: Study 
data suggests > 80% of patients are managed as either BPH-LUTS- or ED-only. 
Average age of BPH-LUTS/ED patients at ED diagnosis suggests patients may suf-
fer from ED years before seeking medical attention (p= 0.002). Presence of the 
co-occurring condition does not appear to impact treatment choice, however, 
a lower proportion of ED patients initiate treatment after diagnosis, compared 
with BPH-LUTS patients.
systemIc DIsorDers/conDItIons – clinical outcomes studies
Psy1
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objeCtives: To analyse the incidence of pain and the need of analgesics dur-
ing haemodialysis sessions, and its impact on Health-Related Quality of Life 
(HRQoL). Methods: Data about the number of sessions in which 172 patients 
showed pain and needed analgesics were collected in 2 haemodialysis units in Spain 
during 3 months. Age, sex, comorbidities, (diabetes and cancer history), time on 
haemodialysis, pain complaints during haemodialysis sessions, intake of analgesics, 
opioids and antidepressant drugs, were collected. Generic HRQoL was assessed by 
means of the computer adaptive test CAT-Health, previously validated, through an 
iPAD. A negative score means that the HRQoL is worse than that of general popula-
tion and a positive score, indicates that it is better. Results: Mean age (S. D) was 
66.87 (13.32), being 44 patients (25.6%) aged over 75 years. 55.8% were male, 34.3% 
diabetic and 11.6% had cancer history. The median time undergoing haemodialysis 
was 51.50 months (27.75-84.50). 81 patients (47.4%) had pain during some session. 
The mean number of haemodialysis sessions with pain was 4.78 (range between 
1 and 21 sessions), which represents 12.7% of the total number of sessions. 67 
patients (39%) were usually taking analgesics, 37 (21.5%) opioids and 29 (16.9%) 
antidepressant drugs. Patients taking analgesics showed worse HRQoL: mean (S. 
objeCtives: The current study looks to explore young children from high-risk fami-
lies in the Taipei City setting. High-risk social welfare intervention was investigated. 
First, differences between enrollees and non-enrollees for medical subsidy program 
among high-risk family whose cases were started in 2009 or 2010 will be looked at. 
Second, the study will try to determine the social welfare intervention’s effective-
ness in increasing application for medical subsidy program and finding any predic-
tors which may have helped or harmed application for enrollment. Methods: The 
study sample included under 6 year old children high-risk families (n= 199). High-
risk family database and medical subsidy database were linked. Differences between 
high-risk subsidy enrollees (n= 87) and non-enrollees (n= 112) and effectiveness of a 
social welfare intervention in increasing subsidy application were investigated in a 
pre-post analysis of high-risk social welfare intervention. Individual level as well as 
relative residential level characteristics were explored. Results: Medical subsidy 
enrollment was correlated with younger age at time of a high-risk intervention and 
relative district level variables. Pre-post comparison suggests high-risk interventions 
significantly increased subsidy application by 7.4%. Logistic regression indicates 
older age at time of intervention was associated with 40% less chance of applica-
tion. ConClusions: The study provides empirical evidence for potential effects of a 
high risk social welfare intervention on the accessibility to health care. Findings also 
show where policy makers can improve intervention in order to address the needs 
children at-risk, especially for different age groups.
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objeCtives: When the WHO launched the Expanded Programme on Immunisation 
(EPI) in 1974, < 5% of the world’s children were vaccinated against polio, measles, 
diphtheria, tetanus, pertussis and tuberculosis. Nowadays coverage rates are 
increasing and more vaccines have been added to the programme. This project 
aims to identify factors associated with successful programmes based on EPI cov-
erage. Methods: The relationship between multiple socio-demographic and eco-
nomic factors and EPI coverage (primarily obtained from the WHO and World Bank) 
was investigated using simple linear regression, Principal Component Analysis (PCA) 
to identify explanatory variables, and finally multiple linear regression analysis. 132 
countries with data on self-funded health care programmes were included in the 
analysis. These were ranked according to Gross National Income (GNI) per capita and 
lower (L), lower-middle (LM), upper-middle (UM) and upper (U) quartiles were identi-
fied. Results: Income (GNI/capita) was not significantly associated with achiev-
ing high EPI coverage rates. Within the income groups the factors trending with 
improved EPI coverage included: 5-yr mortality and corruption index in L, sanitary 
facilities in LM, 5-yr mortality, sanitary facilities, birth-rate and life-expectancy in 
UM. In U all countries achieved > 90% coverage. ConClusions: Identifying simple 
predictive variables of successful vaccination programmes is complex because of 
multicollinearity. However, by exploring within homogeneous income groups, it was 
possible to identify underlying factors related to vaccination programme success. As 
the core EPI vaccines were introduced 40yrs ago one would expect introduction to 
have been fully implemented thus reducing the likelihood of a relationship between 
country income and coverage today, however it could have been expected some time 
ago. To further explore the relationship between country income and vaccination 
programme success, one could expand the analysis to include the newer vaccines 
as soon as coverage information is available for a majority of the countries.
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objeCtives: Despite existing examples of the great impact successful integration 
of PRO science and know-how may have on improving market access, PROs are typi-
cally not part of drug development decision making such as go/no-go decisions. The 
objective of this study is to identify decision making instances in drug development 
when important go/no-go decision making also could have included PROs but typically 
weren’t. Additionally, search for any strategies and activities that might better enhance 
the likelihood for senior decision makers also to integrate PRO science and knowhow 
in drug development decision making. Methods: A literature search was carried 
out including terms such as PRO, strategy, decision-making, go/no-go decisions, drug 
development and phases I to IV. Results: Typical go/no-go decisions mentioned in the 
literature include decisions to move a drug candidate from one development phase to 
the next stage, i. e. from target-to hit to launch decisions. There were very few references 
found where go/no-go decision-making in drug development also included PROs. Many 
references also states the necessity to include the patient (e. g. listen to the patient) early 
on in drug development. However, no concrete suggestions on how to carry out these 
ambitions in practice were found. ConClusions: There is little research to be found in 
the literature on go/no-go decision making in drug development where PRO science and 
knowhow are taken into account. The lack of clear practical guidance and examples on 
when and how to start inclusion of PROs science and knowhow in go/no-go 
decision making may be one impediment to their successful inclusion. Perhaps, a best 
practice rule could be as simple as including a PRO opportunity assessment in phase 
I-II go/no-go decisions where the feasibility, pros and cons for potentially including 
PRO in the clinical development program are summarized. At least, a first overview 
of PROs potential is done.
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